SeekingAlpha · Aug 7, 2026
Amylyx Pharmaceuticals: Avexitide Defines The Endocrine Rebuild
Amylyx shifts to endocrine with avexitide in Phase 3 LUCIDITY for post-bariatric hypoglycemia; cash runway to 2028. Click here to read more.
AM
NASDAQ · AMLX
Amylyx Pharmaceuticals, Inc.
Healthcare · Biotechnology
$22.48
Down-$0.95 (-4.22%)
Updated Aug 14, 2026, 7:05 PM
SID Score
6.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.26B
- P/E ratio
- -9.48
- Dividend yield
- 0.00%
- 52-week range
- $12.44 – $24.60
- Volume
- 839.45K
- Avg. volume
- 1.42M
Price performance
AMLX price history
1M range · 21 trading sessions · Daily adjusted prices
AMLX closed at $22.48 after 21 trading sessions, up 32.08% for the selected period.
- Last close
- $22.48
- Period change
- +32.08%
- Period low
- $17.02
- Period high
- $24.19
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $23.37 | $23.635 | $22.46 | $22.48 | 839.45K |
| Aug 12, 2026 | $23.86 | $24.0848 | $23.30 | $23.35 | 1.45M |
| Aug 11, 2026 | $22.78 | $23.7299 | $22.19 | $23.63 | 833.86K |
| Aug 10, 2026 | $22.68 | $23.03 | $22.00 | $22.67 | 1.33M |
| Aug 7, 2026 | $24.19 | $24.60 | $22.56 | $22.82 | 2.68M |
| Aug 6, 2026 | $21.10 | $24.36 | $21.10 | $24.19 | 3.54M |
| Aug 5, 2026 | $22.06 | $22.1694 | $21.52 | $21.85 | 1.77M |
| Aug 4, 2026 | $20.34 | $22.28 | $20.3245 | $21.87 | 3.43M |
| Aug 3, 2026 | $20.29 | $20.47 | $19.295 | $20.17 | 1.69M |
| Jul 31, 2026 | $20.74 | $20.87 | $19.295 | $20.31 | 1.83M |
| Jul 30, 2026 | $19.69 | $20.94 | $19.31 | $20.75 | 3.55M |
| Jul 29, 2026 | $19.50 | $20.21 | $19.045 | $19.73 | 2.07M |
| Jul 28, 2026 | $19.79 | $19.99 | $18.905 | $19.55 | 3.41M |
| Jul 27, 2026 | $18.50 | $19.60 | $18.08 | $19.49 | 2.58M |
| Jul 24, 2026 | $17.61 | $18.42 | $17.22 | $18.41 | 1.63M |
| Jul 23, 2026 | $17.17 | $18.035 | $17.00 | $17.59 | 816.14K |
| Jul 22, 2026 | $18.33 | $18.65 | $17.685 | $17.70 | 1.56M |
| Jul 21, 2026 | $17.44 | $18.86 | $17.38 | $18.50 | 2.72M |
| Jul 20, 2026 | $18.00 | $18.53 | $17.44 | $17.45 | 1.41M |
| Jul 17, 2026 | $16.70 | $18.08 | $16.52 | $17.75 | 1.25M |
| Jul 16, 2026 | $17.75 | $17.925 | $16.80 | $17.02 | 941.65K |
Latest AMLX news
The latest Smart Investors Daily articles mentioning AMLX.
Stock researchCompany · Overview
AMLX research
Overview
Company profile and research snapshot.
Company profile
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $20.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 3, 2026 | Citigroup | Buy | — |
| Jul 20, 2026 | Mizuho | Outperform | — |
| Jun 25, 2026 | Guggenheim | Buy | — |
| Apr 28, 2026 | Mizuho | Outperform | — |
| Mar 25, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 6, 2026
Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2026 Earnings Call Transcript
Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2026 Earnings Call August 6, 2026 8:00 AM EDTCompany ParticipantsLindsey Allen - Head of Investor Relations &...
ChartMill · Aug 6, 2026
Amylyx Pharmaceuticals (NASDAQ:AMLX) Misses on Q2 Bottom Line as LUCIDITY Readout Looms
Amylyx Pharma (AMLX) Q2 loss misses, stock dips; investors await LUCIDITY trial data on avexitide expected late Aug/early Sep.
Benzinga · Aug 6, 2026
RAmylyx Pharma Q2 EPS $(0.39) Misses $(0.36) Estimate, Cash & Equivalents $279.8M. Cash runway Expected To Fund Operations Till 2028
Amylyx Pharma (NASDAQ:AMLX) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.36) by 8.33 percent. This is a 15.22 percent increase over losses of $(0.46) per share from
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
